ClinicalTrials.gg
CompletedNCT01607294Updated Mar 29, 2019

A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes

A Phase 2 interventional study of ETC-1002 and Placebo in Hyperlipidemia and Type 2 Diabetes, sponsored by Esperion Therapeutics, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-03-29.

Sponsored by Esperion Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 338 studies in Hyperlipidemias with a site in United States — 30 open to participants now, 45 under way, 10 of them phase 3. Hyperlipidemias · United States.

Enrollment
194th of 306
60 · median 120
Started
2012
with 12 others
Phase 2
43 of 338
2 open now
Registered
156th of 338
by date
Lead sponsor
8 of 338
Esperion Therapeutics, Inc.

Among the 338 studies in Hyperlipidemias with a site in United States, this one is the 194th largest by enrollment of the 306 interventional ones that give a count, is one of 13 that started in 2012, is one of 43 in phase 2, and was the 156th registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

30 of the 338 studies in Hyperlipidemias with a site in United States are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 338 studies in Hyperlipidemias with a site in United States, or all of them as a file.
02

Study summary

This Phase 2 study will asses the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes.

03

Conditions studied

  • Hyperlipidemia
  • Type 2 Diabetes
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Diagnosis of type 2 diabetes meeting all of the following:
  • Minimum 6 month history of diabetes prior to screening visit;
  • Fasting C-peptide ≥ 0.8 ng/mL at screening visit;
  • at screening visit 7-10%;
  • Fasting glucose from 140-270 mg/dL on Day -7 following washout of all glucose regulating drugs and supplements.
  • at screening visit from 25-35 kg/m2;
  • LDL-C at screening ≥ 100 mg/dL
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    ETC-1002

    ETC-1002 daily Weeks 1-2, 80 mg/day; Weeks 3-4, 120 mg/day

    Drug: ETC-1002

  • Placebo comparator
    Placebo

    Placebo daily 4 weeks

    Drug: Placebo

Interventions

  • ETC-1002 Daily for 4 weeks

  • DrugPlacebo

    Placebo Daily for 4 weeks

06

What researchers measure

Primary outcomes

  1. assess the LDL-C lowering efficacy of ETC-1002 versus placebo in subjects with type 2 diabetes

    evaluate the change in LDL-C from baseline to various time points

    Time frame: 4 weeks

Secondary outcomes

  1. assess the effect of ETC-1002 versus placebo on glycemic parameters including fasting plasma and postprandial glucose and insulin

    evaluate the change in glucose and insulin from baseline to various time points

    Time frame: 4 weeks

  2. assess the effect of ETC-1002 versus placebo on measures of insulin sensitivity in subjects with type 2 diabetes

    evaluate the change in HOMA-IR from baseline to various time points

    Time frame: 4 weeks

  3. assess safety using adverse event reports, physical exams, vital signs, ECGs and clinical laboratory parameters

    evaluate any changes in safety parameters during the course of the study.

    Time frame: 4 weeks

07

Study locations

1 site
  • Miramar, Florida, United States
08

References and documents

Publications

  • Gutierrez MJ, Rosenberg NL, Macdougall DE, Hanselman JC, Margulies JR, Strange P, Milad MA, McBride SJ, Newton RS. Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014 Mar;34(3):676-83. doi: 10.1161/ATVBAHA.113.302677. Epub 2014 Jan 2. PubMed 24385236 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2012
First posted
May 30, 2012
Start
Apr 2012
Primary completionActual
Oct 2012
CompletionActual
Oct 2012
Results delay requested
Aug 13, 2015
Last update
Mar 29, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01607294
Responsible party
Sponsor
First posted
May 30, 2012
Start date
Apr 2012
Primary completion
Oct 2012
Completion
Oct 2012
Last update
Mar 29, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bempedoic acid

Start the discussion